István Molnár

2.9k total citations · 1 hit paper
45 papers, 2.1k citations indexed

About

István Molnár is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Hematology. According to data from OpenAlex, István Molnár has authored 45 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Hematology. Recurrent topics in István Molnár's work include Thyroid Cancer Diagnosis and Treatment (10 papers), HER2/EGFR in Cancer Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). István Molnár is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (10 papers), HER2/EGFR in Cancer Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). István Molnár collaborates with scholars based in United States, Germany and France. István Molnár's co-authors include Lars Bastholt, Barbara Jarząb, Young Kee Shong, Rossella Elisei, Christelle de la Fouchardière, Johannes W. A. Smit, Salvatore Siena, Steven I. Sherman, Christopher M. Nutting and Marcia S. Brose and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

István Molnár

43 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

2014 1.2k citations Marcia S. Brose, Christopher M. Nutting et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
István Molnár United States	18	1.0k	566	464	277	249	45	2.1k
H. Richard Alexander United States	23	478 0.5×	581 1.0×	477 1.0×	343 1.2×	622 2.5×	63	1.9k
Mimi I. Hu United States	31	1.4k 1.3×	1.6k 2.8×	558 1.2×	474 1.7×	576 2.3×	117	3.3k
T.W.J. Lennard United Kingdom	22	362 0.4×	470 0.8×	357 0.8×	273 1.0×	500 2.0×	71	1.5k
Atsuhiko Sakamoto Japan	28	1.1k 1.0×	1.0k 1.8×	618 1.3×	397 1.4×	648 2.6×	126	3.5k
Masaya Mori Japan	21	334 0.3×	605 1.1×	419 0.9×	363 1.3×	628 2.5×	115	1.9k
Ramona Dadu United States	30	1.8k 1.8×	1.5k 2.6×	477 1.0×	396 1.4×	437 1.8×	94	2.9k
Erich M. Sturgis United States	32	436 0.4×	1.2k 2.1×	1.4k 2.9×	673 2.4×	583 2.3×	80	3.3k
Dhaval Patel United States	28	713 0.7×	620 1.1×	570 1.2×	129 0.5×	654 2.6×	91	2.1k
Mario V. Fiorentino Italy	23	161 0.2×	554 1.0×	320 0.7×	452 1.6×	278 1.1×	80	1.7k
Taro Iguchi Japan	18	237 0.2×	314 0.6×	230 0.5×	1.2k 4.5×	168 0.7×	69	1.6k

Countries citing papers authored by István Molnár

Since Specialization

Citations

This map shows the geographic impact of István Molnár's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by István Molnár with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites István Molnár more than expected).

Fields of papers citing papers by István Molnár

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by István Molnár. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by István Molnár. The network helps show where István Molnár may publish in the future.

Co-authorship network of co-authors of István Molnár

This figure shows the co-authorship network connecting the top 25 collaborators of István Molnár. A scholar is included among the top collaborators of István Molnár based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with István Molnár. István Molnár is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kasoha, Mariz, et al.. (2025). Evaluation of inflammatory serum parameters as a diagnostic tool in patients with endometriosis: a case-control study. Scientific Reports. 15(1). 20172–20172. 1 indexed citations

Melchior, Patrick, et al.. (2025). PD-L1+ CD49f+ CD133+ Circulating tumor cells predict outcome of patients with vulvar or cervical cancer after radio- and chemoradiotherapy. Journal of Translational Medicine. 23(1). 321–321. 1 indexed citations

Münster, Pamela N., Ian E. Krop, Patricia LoRusso, et al.. (2018). Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British Journal of Cancer. 119(9). 1086–1093. 95 indexed citations

Geretti, Elena, Nancy Dumont, Sílvia Coma, et al.. (2016). Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors. Annals of Oncology. 27. vi539–vi539. 1 indexed citations

Miller, Kathy D., Javier Cortés, Sara A. Hurvitz, et al.. (2016). HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 16(1). 352–352. 124 indexed citations

Miller, Kathy D., Javier Cortés, Sara A. Hurvitz, et al.. (2016). HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).. Journal of Clinical Oncology. 34(15_suppl). TPS631–TPS631. 1 indexed citations

Verma, Sunil, Sara A. Hurvitz, Ian E. Krop, et al.. (2016). HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1. Annals of Oncology. 27. vi99–vi99.

Brose, Marcia S., Christopher M. Nutting, Barbara Jarząb, et al.. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet. 384(9940). 319–328. 1153 indexed citations breakdown →

Procopio, Giuseppe, Joaquim Bellmunt, Janice P. Dutcher, et al.. (2013). Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. British Journal of Cancer. 108(2). 311–318. 41 indexed citations

10.

Stehle, John, Wei Du, Mark C. Willingham, et al.. (2011). Novel innate cancer killing activity in humans. Cancer Cell International. 11(1). 26–26. 10 indexed citations

11.

Chirila, Costel, Dawn Odom, Giovanna Devercelli, et al.. (2011). Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. International Journal of Colorectal Disease. 27(5). 623–634. 25 indexed citations

12.

Hurd, David D., Gregory J. Pomper, James Lovato, et al.. (2009). The transplant iron score as a predictor of stem cell transplant survival. Journal of Hematology & Oncology. 2(1). 44–44. 31 indexed citations

13.

Elter, Thomas, István Molnár, Jens Kuhlmann, Michael Hallek, & Clemens‐Martin Wendtner. (2008). Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leukemia & lymphoma. 49(12). 2256–2262. 33 indexed citations

14.

Keung, Yi‐Kong, et al.. (2007). Copper deficiency causes reversible myelodysplasia. American Journal of Hematology. 82(7). 625–630. 59 indexed citations

15.

Hurd, David D., et al.. (2006). Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia. Leukemia Research. 30(10). 1249–1252. 2 indexed citations

16.

Keung, Yi‐Kong, Michael W. Beaty, Bayard L. Powell, et al.. (2004). Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia—retrospective study and review of literature. Leukemia Research. 28(6). 579–586. 74 indexed citations

17.

Molnár, István, Timothy E. Kute, Mark C. Willingham, & Gary G. Schwartz. (2004). 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations. The Journal of Steroid Biochemistry and Molecular Biology. 89-90(1-5). 539–543. 5 indexed citations

18.

Molnár, István, et al.. (2002). Arthritis Associated with Recurrent Erythema Multiforme Responding to Oral Acyclovir. Clinical Rheumatology. 21(5). 415–417. 6 indexed citations

19.

Dahl, Ola E., et al.. (1988). Global tests on coagulation and fibrinolysis in systemic and pulmonary circulation accompanying hip arthroplasty with acrylic cement. Thrombosis Research. 50(6). 865–873. 25 indexed citations

20.

Dahl, Ola E., et al.. (1988). Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement. Thrombosis Research. 50(6). 875–884. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact